Science
A study in the September issue of Gastroenterology evaluated the effects of vedolizumab induction therapy for patients with Crohn's disease for whom tumor necrosis factor (TNF) antagonists have already failed. Dr. Kuemmerle speaks with Dr. Bruce E. Sands